ODT News and Press, Odonate Therapeutics Inc.

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the c...

ODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Odonate Therapeutics, Inc. - ODT ODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, L...

Gainers: Longeveron (NASDAQ:LGVN) +137%. Virtuoso (NASDAQ:VOSOU) +89%. Dicerna (NASDAQ:DRNA) +79%. ClearSign (NASDAQ:CLIR) +33%. Alpine (NASDAQ:ALPP) +22%. Macy's (NYSE:M) +21%. Enthusiast Gaming Holdings (NASDAQ:EGLX) +20%. BJ's (NYSE:BJ) +19%. Jowell Global (NASDAQ:JWEL) +17%. Yatsen Holdin...

Shares of Odonate Therapeutics (ODT -39.5%) are down significantly today after the company said it would begin a share repurchase plan of up to 20M shares. Shares hit a 52-week low of $1.95. In March, shares plummeted after the company said it was discontinuing development of its orally ...

Odonate Therapeutics (NASDAQ:ODT) trades 5.2% down premarket after it commenced a share repurchase plan for up to 20M shares in order to return capital to stockholders. This action is in connection with the company’s earlier announced decision to discontinue the dev...

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company’s previously announced decision to discontinue the deve...

Odonate Therapeutics (NASDAQ:ODT): Q3 GAAP EPS of -$0.37. Press Release As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. For further details see: Odonate Therapeutics reports Q3 results

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate’s cash used in operat...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Odonate Therapeutics, Inc. (NasdaqGS: ODT). On August 24, 2020, the Company disclos...

SAN DIEGO, CA / ACCESSWIRE / August 17, 2021 / The Shareholders Foundation, Inc. announces an update in the lawsuit that is pending for certain investors in (NASDAQ:ODT) shares. Investors, who purchased shares of Odonate Therapeutics, Inc. (NASDAQ:ODT) prior to December 2017 and continue to...